Source: Agency for Science, Technology and Research (A*STAR), Singapore
Date: September 28, 2008
Summary:
Singapore's Institute of Bioengineering and Nanotechnology (IBN), which celebrates its fifth anniversary this year, has invented a unique user-friendly gel that can liquefy on demand, with the potential to revolutionize three-dimensional (3D) cell culture for medical research. As reported in Nature Nanotechnology (Y.S. Pek, A. C. A. Wan, A. Shekaran, L. Zhuo and J. Y. Ying, "A Thixotropic Nanocomposite Gel for Three-Dimensional Cell Culture"), IBN's novel gel media has the unique ability to liquefy when it is subjected to a moderate shear force and rapidly resolidifies into a gel within one minute upon removal of the force. This phenomenon of reverting between a gel and a liquid state is known as thixotropy.
Another key feature of IBN's gel is the ease with which researchers can transfer the cultured cells from the matrix by pipetting the required amount from the liquefied gel. Unlike conventional cell culture, trypsin is not required to detach the cultured cells from the solid media. As trypsin is an enzyme that is known to damage cells, especially in stem cell cultures, the long-term quality and viability of cells cultured using IBN's thixotropic gel would improve substantially without the exposure to this enzyme. Researchers are also able to control the gel's stiffness, thus facilitating the differentiation of stem cells into specific cell types.
Monday, September 29, 2008
Thursday, September 25, 2008
Important new step toward producing stem cells for human treatment
Source: Harvard University
Date: September 25, 2008
Summary:
A team of Harvard Stem Cell Institute (HSCI) scientists has taken an important step toward producing induced pluripotent stem (iPS) cells that are safe to transplant into patients to treat diseases. Excitement over the ability of researchers to create this form of stem cell by inserting four genes into adults cells has thus far been tempered by the fact that the genes have been inserted using retroviruses, which have the potential to turn on cancer genes and trigger tumor growth. But today Konrad Hochedlinger and HSCI colleagues at Massachusetts General Hospital and Joslin Diabetes Center report having created mouse iPS cells using harmless adenoviruses that ultimately disappear from the new cells and therefore do not integrate into their DNA like the retroviruses.
Date: September 25, 2008
Summary:
A team of Harvard Stem Cell Institute (HSCI) scientists has taken an important step toward producing induced pluripotent stem (iPS) cells that are safe to transplant into patients to treat diseases. Excitement over the ability of researchers to create this form of stem cell by inserting four genes into adults cells has thus far been tempered by the fact that the genes have been inserted using retroviruses, which have the potential to turn on cancer genes and trigger tumor growth. But today Konrad Hochedlinger and HSCI colleagues at Massachusetts General Hospital and Joslin Diabetes Center report having created mouse iPS cells using harmless adenoviruses that ultimately disappear from the new cells and therefore do not integrate into their DNA like the retroviruses.
Thursday, September 18, 2008
Key Advance In Treating Spinal Cord Injuries Found In Manipulating Stem Cells
Source: University of Rochester Medical Center
Date: September 18, 2008
Summary:
Manipulating embryo-derived stem cells prior to transplantation may hold the key to overcoming a critical obstacle to using stem cell technology to repair spinal cord injuries, scientists have shown. Research from a team of scientists from the University of Rochester Medical Center and the University of Colorado Denver School of Medicine, published today in the online Journal of Biology, may lead to improved spinal cord repair methods that pave the way for victims of paralysis to recover the use of their bodies without the risk of transplant-induced pain syndromes.
Date: September 18, 2008
Summary:
Manipulating embryo-derived stem cells prior to transplantation may hold the key to overcoming a critical obstacle to using stem cell technology to repair spinal cord injuries, scientists have shown. Research from a team of scientists from the University of Rochester Medical Center and the University of Colorado Denver School of Medicine, published today in the online Journal of Biology, may lead to improved spinal cord repair methods that pave the way for victims of paralysis to recover the use of their bodies without the risk of transplant-induced pain syndromes.
Different stem cell types defined by exclusive combinations of genes working together
Source: Agency for Science, Technology and Research (A*STAR), Singapore
Date: September 18, 2008
Summary:
In the new issue of Cell Stem Cell, scientists at the Genome Institute of Singapore report that the same transcription factor, which is crucial for the survival of different stem cell types, can behave differently. This study clearly showed for the first time that different types of stem cells are defined by exclusive combinations of genes working together, and this is under the influence of a single key stem cell factor (called Sall4).
The finding is timely since other researchers have recently revealed that specific genetic recipes can be used to turn non-stem cells into different stem cells that can be useful clinically. This finding reveals important insights about how scientists may be able to manipulate and engineer different stem cells for the treatment of human degenerative disorders. Understanding the behaviour of transcription factors, a class of gene regulators, helps pave the way for important advancements in stem cell technology and clinical research.
Date: September 18, 2008
Summary:
In the new issue of Cell Stem Cell, scientists at the Genome Institute of Singapore report that the same transcription factor, which is crucial for the survival of different stem cell types, can behave differently. This study clearly showed for the first time that different types of stem cells are defined by exclusive combinations of genes working together, and this is under the influence of a single key stem cell factor (called Sall4).
The finding is timely since other researchers have recently revealed that specific genetic recipes can be used to turn non-stem cells into different stem cells that can be useful clinically. This finding reveals important insights about how scientists may be able to manipulate and engineer different stem cells for the treatment of human degenerative disorders. Understanding the behaviour of transcription factors, a class of gene regulators, helps pave the way for important advancements in stem cell technology and clinical research.
Wednesday, September 17, 2008
Scientists turn human skin cells into insulin-producing cells
Source: University of North Carolina
Date: September 17, 2008
Summary:
Researchers at the University of North Carolina at Chapel Hill School of Medicine have transformed cells from human skin into cells that produce insulin, the hormone used to treat diabetes. The breakthrough may one day lead to new treatments or even a cure for the millions of people affected by the disease, researchers say.
The approach involves reprogramming skin cells into pluripotent stem cells, or cells that can give rise to any other fetal or adult cell type, and then inducing them to differentiate, or transform, into cells that perform a particular function – in this case, secreting insulin. Several recent studies have shown that cells can be returned to pluripotent state using "defined factors" (specific proteins that control which genes are active in a cell), a technique pioneered by Dr. Shinya Yamanaka, a professor at Kyoto University in Japan. However, the UNC study is the first to demonstrate that cells reprogrammed in this way can be coaxed to differentiate into insulin-secreting cells. Results of the study are published online in the Journal of Biological Chemistry.
Date: September 17, 2008
Summary:
Researchers at the University of North Carolina at Chapel Hill School of Medicine have transformed cells from human skin into cells that produce insulin, the hormone used to treat diabetes. The breakthrough may one day lead to new treatments or even a cure for the millions of people affected by the disease, researchers say.
The approach involves reprogramming skin cells into pluripotent stem cells, or cells that can give rise to any other fetal or adult cell type, and then inducing them to differentiate, or transform, into cells that perform a particular function – in this case, secreting insulin. Several recent studies have shown that cells can be returned to pluripotent state using "defined factors" (specific proteins that control which genes are active in a cell), a technique pioneered by Dr. Shinya Yamanaka, a professor at Kyoto University in Japan. However, the UNC study is the first to demonstrate that cells reprogrammed in this way can be coaxed to differentiate into insulin-secreting cells. Results of the study are published online in the Journal of Biological Chemistry.
Scientists identify genes capable of regulating stem cell function
Source: Forsyth Institute
Date: September 17, 2008
Summary:
Scientists from The Forsyth Institute, Boston, MA, and the Howard Hughes Medical Institute at the University of Utah School of Medicine have developed a new system in which to study known mammalian adult stem cell disorders. This research, conducted with the flatworm planaria, highlights the genetic similarity between these invertebrates and mammals in the mechanisms by which stem cell regulatory pathways are used during adult tissue maintenance and regeneration. It is expected that this work may help scientists pursue pharmacological, genetic, and physiological approaches to develop potential therapeutic targets that could repair or prevent abnormal stem cell growth which can lead to cancer.
Date: September 17, 2008
Summary:
Scientists from The Forsyth Institute, Boston, MA, and the Howard Hughes Medical Institute at the University of Utah School of Medicine have developed a new system in which to study known mammalian adult stem cell disorders. This research, conducted with the flatworm planaria, highlights the genetic similarity between these invertebrates and mammals in the mechanisms by which stem cell regulatory pathways are used during adult tissue maintenance and regeneration. It is expected that this work may help scientists pursue pharmacological, genetic, and physiological approaches to develop potential therapeutic targets that could repair or prevent abnormal stem cell growth which can lead to cancer.
Muscle stem cell identity confirmed by Stanford researchers
Source: Stanford University Medical Center
Date: September 17, 2008
Summary:
A single cell can repopulate damaged skeletal muscle in mice, say scientists at the Stanford University School of Medicine, who devised a way to track the cell's fate in living animals. The research is the first to confirm that so-called satellite cells encircling muscle fibers harbor an elusive muscle stem cell. Identifying and isolating such a cell in humans would have profound therapeutic implications for disorders such as muscular dystrophy, injury and muscle wasting due to aging, disuse or disease.
Date: September 17, 2008
Summary:
A single cell can repopulate damaged skeletal muscle in mice, say scientists at the Stanford University School of Medicine, who devised a way to track the cell's fate in living animals. The research is the first to confirm that so-called satellite cells encircling muscle fibers harbor an elusive muscle stem cell. Identifying and isolating such a cell in humans would have profound therapeutic implications for disorders such as muscular dystrophy, injury and muscle wasting due to aging, disuse or disease.
Tuesday, September 16, 2008
Engineered stem cells carry promising ALS therapy
Source: University of Wisconsin
Date: September 16, 2008
Summary:
Using adult stem cells from bone marrow as "Trojan horses"to deliver a nurturing growth factor to atrophied muscles, Wisconsin scientists have successfully slowed the progression of ALS in rats. The work, published this week (Sept. 16) in the journal Molecular Therapy, provides a tantalizing hint that the approach may provide a new therapy for people with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Date: September 16, 2008
Summary:
Using adult stem cells from bone marrow as "Trojan horses"to deliver a nurturing growth factor to atrophied muscles, Wisconsin scientists have successfully slowed the progression of ALS in rats. The work, published this week (Sept. 16) in the journal Molecular Therapy, provides a tantalizing hint that the approach may provide a new therapy for people with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.
Monday, September 15, 2008
Embryonic stem cells might help reduce transplantation rejection
Source: University of Iowa
Date: September 15, 2008
Summary:
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs. The University of Iowa and the Iowa City Veterans Affairs (VA) Medical Center finding has implications for possible improvements in organ and bone marrow transplantation for humans. The study results appeared Friday in the online journal PLoS ONE.
Date: September 15, 2008
Summary:
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs. The University of Iowa and the Iowa City Veterans Affairs (VA) Medical Center finding has implications for possible improvements in organ and bone marrow transplantation for humans. The study results appeared Friday in the online journal PLoS ONE.
Thursday, September 11, 2008
DNA "Tattoos" Link Adult, Daughter Stem Cells...
Source: University of Utah Health Sciences
Date: September 11, 2008
Summary:
Unlike some parents, adult stem cells don’t seem to mind when their daughters get a tattoo. In fact, they’re willing to pass them along. Using the molecular equivalent of a tattoo on DNA that adult stem cells (ASC) pass to their “daughter” cells in combination with gene expression profiles, University of Utah. researchers have identified two early steps in adult stem cell differentiation—the process that determines whether cells will form muscle, neurons, skin, etc., in people and animals. The U of U researchers, led by Alejandro Sánchez Alvarado, Ph.D., professor of neurobiology and anatomy, identified 259 genes that help defined the earliest steps in the differentiation of adult stem cells in planarians—tiny flatworms that have the uncanny ability to regenerate cells and may have much to teach about human stem cell biology. The findings, reported in the Sept. 11 issue of Cell Stem Cell establish planarians as an excellent model for studying adult stem cells in a live animal, rather than a laboratory culture dish.
Date: September 11, 2008
Summary:
Unlike some parents, adult stem cells don’t seem to mind when their daughters get a tattoo. In fact, they’re willing to pass them along. Using the molecular equivalent of a tattoo on DNA that adult stem cells (ASC) pass to their “daughter” cells in combination with gene expression profiles, University of Utah. researchers have identified two early steps in adult stem cell differentiation—the process that determines whether cells will form muscle, neurons, skin, etc., in people and animals. The U of U researchers, led by Alejandro Sánchez Alvarado, Ph.D., professor of neurobiology and anatomy, identified 259 genes that help defined the earliest steps in the differentiation of adult stem cells in planarians—tiny flatworms that have the uncanny ability to regenerate cells and may have much to teach about human stem cell biology. The findings, reported in the Sept. 11 issue of Cell Stem Cell establish planarians as an excellent model for studying adult stem cells in a live animal, rather than a laboratory culture dish.
Stem cell regeneration repairs congenital heart defect
Source: Mayo Clinic
Date: September 11, 2008
Mayo Clinic investigators have demonstrated that stem cells can be used to regenerate heart tissue to treat dilated cardiomyopathy, a congenital defect. Publication of the discovery was expedited by the editors of Stem Cells and appeared online in the "express" section of the journal's Web site. The study expands on the use of embryonic stem cells to regenerate tissue and repair damage after heart attacks and demonstrates that stem cells also can repair the inherited causes of heart failure.
Date: September 11, 2008
Mayo Clinic investigators have demonstrated that stem cells can be used to regenerate heart tissue to treat dilated cardiomyopathy, a congenital defect. Publication of the discovery was expedited by the editors of Stem Cells and appeared online in the "express" section of the journal's Web site. The study expands on the use of embryonic stem cells to regenerate tissue and repair damage after heart attacks and demonstrates that stem cells also can repair the inherited causes of heart failure.
Scientists isolate cancer stem cells
Source: University of Oklahoma
Date: September 11, 2008
Summary:
After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning. A research team at the University of Oklahoma led by Courtney Houchen, M.D., and Shrikant Anant, Ph.D., discovered that a particular protein only appears in stem cells. Until now, researchers knew of proteins that appeared in both regular cancer cells and stem cells, but none that just identified a stem cell. The group has already begun work to use the protein as a target for a new compound that once developed would kill the stem cells and kill the cancer. By targeting the stem cells, scientists and physicians also would be able to stop the cancer from returning.
Date: September 11, 2008
Summary:
After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning. A research team at the University of Oklahoma led by Courtney Houchen, M.D., and Shrikant Anant, Ph.D., discovered that a particular protein only appears in stem cells. Until now, researchers knew of proteins that appeared in both regular cancer cells and stem cells, but none that just identified a stem cell. The group has already begun work to use the protein as a target for a new compound that once developed would kill the stem cells and kill the cancer. By targeting the stem cells, scientists and physicians also would be able to stop the cancer from returning.
Tuesday, September 09, 2008
Human embryonic stem cell secretions minimized tissue injury after heart attack
Source: Agency for Science, Technology and Research (A*STAR), Singapore
Date: September 9, 2008
Summary:
A novel way to improve survival and recovery rate after a heart attack was reported in the journal Stem Cell Research by scientists at Singapore's Institute of Medical Biology (IMB) and Bioprocessing Technology Institute (BTI) and The Netherlands' University Medical Center Utrecht. This method, developed in laboratory research with pigs, is the first non-cell based therapeutic application of human embryonic stem cells (hESCs). It entails using secretions from stem cells.
In their studies with pigs, the researchers found that the administration of secretion from stem cells minimized heart injury by enhancing reperfusion therapy (angioplasty and cardiac bypass surgery) and reducing tissue death by another 60%. Heart function was also markedly improved, the scientists report in the paper, published in the June 2008 issue of the journal. By demonstrating the efficacy of this secretion in an experimental pig model, currently the best approximation to a human heart attack patient undergoing reperfusion therapy, the researchers say that they have addressed the longstanding problem of reperfusion injury in the most clinically relevant experimental setting.
Date: September 9, 2008
Summary:
A novel way to improve survival and recovery rate after a heart attack was reported in the journal Stem Cell Research by scientists at Singapore's Institute of Medical Biology (IMB) and Bioprocessing Technology Institute (BTI) and The Netherlands' University Medical Center Utrecht. This method, developed in laboratory research with pigs, is the first non-cell based therapeutic application of human embryonic stem cells (hESCs). It entails using secretions from stem cells.
In their studies with pigs, the researchers found that the administration of secretion from stem cells minimized heart injury by enhancing reperfusion therapy (angioplasty and cardiac bypass surgery) and reducing tissue death by another 60%. Heart function was also markedly improved, the scientists report in the paper, published in the June 2008 issue of the journal. By demonstrating the efficacy of this secretion in an experimental pig model, currently the best approximation to a human heart attack patient undergoing reperfusion therapy, the researchers say that they have addressed the longstanding problem of reperfusion injury in the most clinically relevant experimental setting.
Monday, September 08, 2008
Hadassah Hospital Study Shows That Neural Cells Derived From Human Embryonic Stem Cells Reduce Multiple Sclerosis (MS) Symptoms
Source: Hadasit
Date: September 8, 2008
Summary:
Hadassah University Hospital and Hadasit, the technology transfer company of Hadassah Medical Organization, announced today that scientists at Hadassah University Hospital have discovered a new application for human embryonic stem cells. They have demonstrated for the first time that transplanted neural cells derived from human embryonic stem cells can reduce the clinical symptoms in animals with a form of multiple sclerosis.
Date: September 8, 2008
Summary:
Hadassah University Hospital and Hadasit, the technology transfer company of Hadassah Medical Organization, announced today that scientists at Hadassah University Hospital have discovered a new application for human embryonic stem cells. They have demonstrated for the first time that transplanted neural cells derived from human embryonic stem cells can reduce the clinical symptoms in animals with a form of multiple sclerosis.
Thursday, September 04, 2008
Scientists reveal changes to embryonic stem cells caused by Down syndrome
Source: Queen Mary, University of London
Date: 4 September 2008
Summary:
Scientists investigating the mechanisms of Down Syndrome (DS) have revealed the earliest developmental changes in embryonic stem cells caused by an extra copy of human chromosome 21 – the aberrant inheritance of which results in the condition. Their study is published online today (Thursday 4 September) in the American Journal of Human Genetics.
Lead by Dean Nizetic, Professor of Cellular and Molecular Biology at Barts and The London School of Medicine and Dentistry, the team utilised embryonic stem cells from a previously genetically engineered species of mice carrying a copy of human chromosome 21. They discovered that extra chromosome 21 - a genetic state known as trisomy 21 - disturbs a key regulating gene called NRSF or REST, which in turn disturbs the cascade of other genes that control normal development at the embryonic stem cell stage. Furthermore, they identified one gene (DYRK1A) on human chromosome 21, whose overdose in trisomy (DS), is responsible for the observed effects.
Date: 4 September 2008
Summary:
Scientists investigating the mechanisms of Down Syndrome (DS) have revealed the earliest developmental changes in embryonic stem cells caused by an extra copy of human chromosome 21 – the aberrant inheritance of which results in the condition. Their study is published online today (Thursday 4 September) in the American Journal of Human Genetics.
Lead by Dean Nizetic, Professor of Cellular and Molecular Biology at Barts and The London School of Medicine and Dentistry, the team utilised embryonic stem cells from a previously genetically engineered species of mice carrying a copy of human chromosome 21. They discovered that extra chromosome 21 - a genetic state known as trisomy 21 - disturbs a key regulating gene called NRSF or REST, which in turn disturbs the cascade of other genes that control normal development at the embryonic stem cell stage. Furthermore, they identified one gene (DYRK1A) on human chromosome 21, whose overdose in trisomy (DS), is responsible for the observed effects.
Wednesday, September 03, 2008
Hearing Restoration May Be Possible With Cochlear Repair After Transplant Of Human Cord Blood Cells
Source: Cell Transplantation Center
Date: September 3, 2008
Summary:
Hearing loss due to cochlear damage may be repaired by transplanting human umbilical cord hematopoietic stem cells. This study, using animal models of chemical and auditory cochlear damage, found that when transplanted stem cells migrated to the damaged area, "surprisingly few" transplanted cells were necessary to help repair sensory hair cells and neurons. Researchers say transplanting umbilical cord stem cells provides hope for the repair of human hearing impairments rising from cochlear damage.
Date: September 3, 2008
Summary:
Hearing loss due to cochlear damage may be repaired by transplanting human umbilical cord hematopoietic stem cells. This study, using animal models of chemical and auditory cochlear damage, found that when transplanted stem cells migrated to the damaged area, "surprisingly few" transplanted cells were necessary to help repair sensory hair cells and neurons. Researchers say transplanting umbilical cord stem cells provides hope for the repair of human hearing impairments rising from cochlear damage.
Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
Source: Sangamo BioSciences, Inc.
Date: September 3, 2008
Summary:
Sangamo BioSciences, Inc. announced that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure. Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.
Date: September 3, 2008
Summary:
Sangamo BioSciences, Inc. announced that it has opened a Phase 2 clinical trial (SB-509-801) to evaluate its drug, SB-509, in subjects with ALS, a progressive, degenerative motor-neuron disease for which there are limited treatment options and no cure. Sangamo's drug, SB-509, is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A). SB-509 is also in three additional Phase 2 clinical trials for diabetic neuropathy and stem cell mobilization. VEGF-A has been shown to have nerve protection properties as well as promoting nerve, blood vessel and muscle growth.
Two studies involving cardiac cell transplantation have shown an evolving role for bone marrow cells in cardiac cell therapy
Source: Cell Transplantation: The Regenerative Medicine Journal
Date: September 3, 2008
Summary:
Two studies involving cardiac cell transplantation have shown an evolving role for bone marrow cells in cardiac cell therapy. The implantation of heart muscle cells and subsequent restoration of cardiac function was enhanced when bone marrow cells were implanted along with the cardiomyocytes. Researchers also found that mesenchymal stem cells derived from bone marrow provided an advantage over fetal amniotic fluid derived cells when differentiating into appropriate cells for cardiac cell transplantation and repair.
Date: September 3, 2008
Summary:
Two studies involving cardiac cell transplantation have shown an evolving role for bone marrow cells in cardiac cell therapy. The implantation of heart muscle cells and subsequent restoration of cardiac function was enhanced when bone marrow cells were implanted along with the cardiomyocytes. Researchers also found that mesenchymal stem cells derived from bone marrow provided an advantage over fetal amniotic fluid derived cells when differentiating into appropriate cells for cardiac cell transplantation and repair.
Tuesday, September 02, 2008
New stem cell tools to aid drug development
Source: Durham University
Date: September 2, 2008
Summary:
Scientists have designed, developed and tested new molecular tools for stem cell research to direct the formation of certain tissue types for use in drug development programmes. A collaborative team of scientists from Durham University and the North East England Stem Cell Institute (NESCI) have developed two synthetic molecules which can be used to coax stem cells to 'differentiate' - that is, transform into other forms of tissue. Their use could also help reduce the number of animals used in laboratory research. The team's results are published in the current issue of the scientific journal, Organic and Biomolecular Chemistry.
Date: September 2, 2008
Summary:
Scientists have designed, developed and tested new molecular tools for stem cell research to direct the formation of certain tissue types for use in drug development programmes. A collaborative team of scientists from Durham University and the North East England Stem Cell Institute (NESCI) have developed two synthetic molecules which can be used to coax stem cells to 'differentiate' - that is, transform into other forms of tissue. Their use could also help reduce the number of animals used in laboratory research. The team's results are published in the current issue of the scientific journal, Organic and Biomolecular Chemistry.
Subscribe to:
Posts (Atom)